National Cancer Institute, Naples
2 clinical trials · 2 recruiting · OTHER
Trials by National Cancer Institute, Naples
RECRUITINGPhase 2NCT07213570
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long...
Sponsor: National Cancer Institute, NaplesEnrolling: 601 location
Colorectal Cancer Metastatic
RECRUITINGNCT06032975
PRO for Fighting FT in Ovarian Cancer
Non-profit, multicenter, prospective, observational study. This study aims to evaluate whether the articulated treatment algorithm that is now possible for OC patients does...
Sponsor: National Cancer Institute, NaplesEnrolling: 2401 location
Ovarian Cancer